A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

It's only the first day of summer and record high temperatures are already being reported across much of the U.S. with a ...

This valuable manuscript investigates the localisation of nutrient receptors in bloodstream stage trypanosomes, with implications for both nutrient uptake and immune evasion. Results after direct ...

Beta receptors (beta-1, beta-2 and beta-3) are more involved in heart rate, muscle relaxation and metabolic functions. Understanding alpha receptors vs. beta receptors is essential for ...

Long-Term Beta-Cell Restoration Potential: Insulin deficient patients who received icovamenib (n=45) demonstrated a persistent increase in C-peptide levels beyond the active treatment period, over 3 ...

We showed in the mouse experiments that beta-2 and beta-3 were the important beta-adrenergic receptors, not beta-1. Once we had that result, ...

According to Loomba, up to 75% of VK2809-treated patients achieved MASH resolution with no worsening of fibrosis vs. 29.3% of placebo-treated patients (P < .0001).